Clinical Trial Detail

NCT ID NCT01285037
Title A Study of LY2801653 in Advanced Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

Therapies

Cisplatin

Cetuximab

Merestinib

Age Groups: adult senior

No variant requirements are available.